<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Chloroquine and hydroxychloroquine belonging to the class of 4-aminoquinolines are primarily used as antimalarials. Structurally, hydroxychloroquine differs from chloroquine by the presence of one extra hydroxyl group. Besides its antimalarial prowess, chloroquine has established itself as a broad-spectrum antiviral agent exhibiting potent activity against both DNA and RNA viruses 
 <xref rid="b0600" ref-type="bibr">[120]</xref>, 
 <xref rid="b0605" ref-type="bibr">[121]</xref>, 
 <xref rid="b0610" ref-type="bibr">[122]</xref>, 
 <xref rid="b0615" ref-type="bibr">[123]</xref>. Concerning coronaviruses, chloroquine has been reported to be potent against the SARS-CoV-1 
 <xref rid="b0620" ref-type="bibr">[124]</xref>. A recent report by Wang et al. shed light on the antiviral prowess of chloroquine against the SARS-CoV-2. Chloroquine effectively blocked the viral infection with a high selectivity index (EC
 <sub>50</sub> = 1.13 µM) 
 <xref rid="b0310" ref-type="bibr">[62]</xref>. Gao et al., in a recent publication, disclosed that chloroquine treatment offered superior efficacy than control treatment in a trial that involved a hundred infected patients 
 <xref rid="b0625" ref-type="bibr">[125]</xref>.
</p>
